(NYSE:DGX) New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialties SECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced an advanced...
Related Questions
How will the launch of Quest Diagnostics' advanced pharmacogenomics service affect its revenue forecasts and valuation?
What is the expected market adoption rate for PGx testing relative to competitors like Labcorp and 23andMe, and how might this influence Quest's market share?
Are there any regulatory or reimbursement risks that could impact the profitability of the new PGx offering and the stock price?